Travere Therapeutics (TVTX) to Announce Earnings on Tuesday

Travere Therapeutics (NASDAQ:TVTX) is expected to issue its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect the company to post earnings of ($0.1346) per share and revenue of $157.2660 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Monday, May 4th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.29. The company had revenue of $127.20 million for the quarter, compared to analyst estimates of $136.23 million. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The business’s revenue was up 55.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.47) earnings per share. On average, analysts expect Travere Therapeutics to post $-1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Travere Therapeutics Price Performance

Shares of TVTX stock opened at $55.89 on Friday. Travere Therapeutics has a 52 week low of $15.03 and a 52 week high of $60.10. The stock has a market capitalization of $5.20 billion, a PE ratio of -242.99 and a beta of 1.10. The company has a debt-to-equity ratio of 3.16, a quick ratio of 3.08 and a current ratio of 3.13. The stock’s fifty day moving average is $53.56 and its 200-day moving average is $40.24.

Insider Activity

In other Travere Therapeutics news, insider Elizabeth E. Reed sold 2,076 shares of the company’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $43.95, for a total transaction of $91,240.20. Following the transaction, the insider directly owned 105,211 shares in the company, valued at approximately $4,624,023.45. This represents a 1.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Timothy Coughlin sold 10,000 shares of the firm’s stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $50.07, for a total transaction of $500,700.00. Following the completion of the transaction, the director directly owned 56,250 shares in the company, valued at $2,816,437.50. This trade represents a 15.09% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 103,663 shares of company stock worth $4,730,462. Corporate insiders own 4.44% of the company’s stock.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Raymond James Financial Inc. bought a new stake in shares of Travere Therapeutics during the 2nd quarter valued at $33,000. State of Wyoming bought a new position in shares of Travere Therapeutics in the 4th quarter worth $37,000. Smartleaf Asset Management LLC grew its stake in shares of Travere Therapeutics by 69.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company’s stock worth $45,000 after purchasing an additional 487 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Travere Therapeutics during the second quarter worth $73,000. Finally, Empowered Funds LLC bought a new stake in Travere Therapeutics in the fourth quarter valued at about $115,000.

Wall Street Analyst Weigh In

TVTX has been the topic of several research reports. Wall Street Zen downgraded shares of Travere Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Wells Fargo & Company raised their price objective on shares of Travere Therapeutics from $50.00 to $65.00 and gave the company an “overweight” rating in a research report on Friday, June 12th. Canaccord Genuity Group boosted their target price on shares of Travere Therapeutics from $56.00 to $62.00 and gave the stock a “buy” rating in a research note on Thursday. Wedbush increased their price target on shares of Travere Therapeutics from $55.00 to $61.00 and gave the company an “outperform” rating in a research note on Monday, June 22nd. Finally, Guggenheim raised their price target on shares of Travere Therapeutics from $56.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, June 25th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $52.58.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.